A
A. Gregory DiRienzo
Researcher at Harvard University
Publications - 6
Citations - 870
A. Gregory DiRienzo is an academic researcher from Harvard University. The author has contributed to research in topics: Regimen & Nonparametric statistics. The author has an hindex of 5, co-authored 6 publications receiving 858 citations.
Papers
More filters
Journal ArticleDOI
Class-Sparing Regimens for Initial Treatment of HIV-1 Infection
Sharon A. Riddler,Richard Haubrich,A. Gregory DiRienzo,Lynne Peeples,William G. Powderly,Karin L. Klingman,Kevin W. Garren,Tania George,James F. Rooney,Barbara Brizz,Umesh G. Lalloo,Robert L. Murphy,Susan Swindells,Diane V. Havlir,John W. Mellors +14 more
TL;DR: The virologic efficacy of the NRTI-sparing regimen was similar to that of the efavirenz regimen but was more likely to be associated with drug resistance.
Journal ArticleDOI
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression
Susan Swindells,A. Gregory DiRienzo,Timothy J. Wilkin,Courtney V. Fletcher,David M. Margolis,Gary Thal,Catherine Godfrey,Barbara Bastow,M. Graham Ray,Hongying Wang,Robert W. Coombs,John E. McKinnon,John W. Mellors +12 more
TL;DR: Preliminary data suggest that simplified maintenance therapy with atazanavir-ritonavir alone may be efficacious for maintaining virologic suppression in carefully selected patients with HIV infection.
Journal ArticleDOI
Efficacy of trimethoprim-sulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection.
A. Gregory DiRienzo,Charles van der Horst,Dianne M. Finkelstein,Peter T. Frame,Samuel A. Bozzette,Karen T. Tashima +5 more
TL;DR: In patients with advanced HIV infection not taking highly active antiretroviral therapy, the treatment strategy that initiates prophylaxis with TMP-SMZ is superior to those initiating with AP or DAP for preventing any bacterial infection, with most of the advantage manifested through infectious diarrhea, sinusitis/otitis media, and pneumonia.
Journal ArticleDOI
Non-parametric methods to predict HIV drug susceptibility phenotype from genotype.
TL;DR: From these methods, eight codons from the protease region of the HIV genome that predict resistance to amprenavir are identified, and pairs of codons that tend either to occur together or to preclude the occurrence of the other member of the pair are determined.
Journal ArticleDOI
Design and analysis of clinical trials with a bivariate failure time endpoint, with application to AIDS Clinical Trials Group Study A5142
TL;DR: This article outlines the bivariate endpoint of time to virological failure and time to regimen termination and compares their small sample properties using the simulation study that was executed for the purpose of designing a current AIDS clinical trial.